T cell activation requires a T cell receptor (TCR) to recognize its cognate peptide in the context of an MHC molecule. In addition, the association of CD3 with the TCR–peptide–MHC complex ...

The T-cell co-receptor CD4 is required for T-cell activation, and it may be involved in stabilization of the T-cell receptor and class II major histocompatibility complexes during antigen ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

This can increase receptor sensitivity while reducing cytotoxicity and T cell exhaustion observed with a CAR. 11,12 (8) Synthetic TCR antigen receptor/HLA-independent TCR (STAR/HIT) constructs retain ...

S3). Immunohistochemical analysis showed a dense lymphocytic infiltration of the lamina propria positive for T-cell receptor (TCR) α, CD3, CD4, and granzyme B but which did not express TRBC1 ...

A bispecific antibody (BsAb) is a type of artificial protein with the ability to bind to two distinct antigens or two epitopes of one antigen at the same time. Bispecific antibodies can assume a ...

a bispecific T cell engager (BiTE) that consists of a soluble TCR targeting gp100 expressed on cancer cells fused to a protein that binds CD3 receptors on lymphocytes – as a treatment for ...

PSMA has demonstrated potential as a T cell engager target for prostate cancer. Xilio anticipates nominating a development candidate for its PSMA program in the ATACR format in the third quarter of ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

SIM0500 targets G-protein-coupled receptor class 5 member D (GPRC5D), cluster of differentiation 3 (CD3) and B-cell maturation antigen (BCMA). Developed using Simcere’s T-cell engager ...

Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced ...